drugset / Trial / NCT05346393
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
Recruiting
124 enrolled
Jena University Hospital
German Research Foundation · collabUniversity Hospital Halle (Saale) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study compares the effectiveness and safety of TIPS implantation in patients with HRS-AKI (stage1, 2 and 3) and liver cirrhosis with standard therapy (drug therapy with terlipressin + albumin).
Timeline
- Start
- 2022-11-29
- Primary completion
- 2025-06
- Completion
- 2026-06
Publications
- Gonzalez-Garay AG, Serralde-Zuniga AE, Velasco Hidalgo L, Flores Garcia NC, Aguirre-Salgado MI. Transjugular intrahepatic portosystemic shunts for adults with hepatorenal syndrome. Cochrane Database Syst Rev. 2024 Jan 18;1(1):CD011039. doi: 10.1002/14651858.CD011039.pub2.
- Ripoll C, Platzer S, Franken P, Aschenbach R, Wienke A, Schuhmacher U, Teichgraber U, Stallmach A, Steighardt J, Zipprich A; Liver-HERO Study Group. Liver-HERO: hepatorenal syndrome-acute kidney injury (HRS-AKI) treatment with transjugular intrahepatic portosystemic shunt in patients with cirrhosis-a randomized controlled trial. Trials. 2023 Apr 5;24(1):258. doi: 10.1186/s13063-023-07261-9.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Albumin | Protein / enzyme biologic | — | — |
| Comparator | Terlipressin | Peptide | — | — |
| Comparator | Noradrenaline | Unknown | — | — |